Cabaletta Bio News

EDIT, CLNE and NIU Are Among After Hour Movers

Seeking AlphaApr 27 05:00

Cabaletta Bio Is Maintained at Buy by Citigroup

Cabaletta Bio Is Maintained at Buy by Citigroup

Dow JonesApr 4 23:57

Citigroup Maintains Buy on Cabaletta Bio, Raises Price Target to $30

Citigroup analyst Samantha Semenkow maintains Cabaletta Bio with a Buy and raises the price target from $26 to $30.

Analyst UpgradesApr 4 23:47

Analysts Offer Insights on Healthcare Companies: Alcon (ALC) and Cabaletta Bio (CABA)

TipRanksApr 4 17:20

Analysts Offer Insights on Healthcare Companies: AbSci (ABSI), HilleVax, Inc (HLVX) and Cabaletta Bio (CABA)

TipRanksMar 26 10:10

Cabaletta Bio Issued ID#NCT06328777 For Phase 1/2 Open-Label Study To Evaluate The Safety And Efficacy Of CABA-201, A CD19-CAR T Cell Therapy, In Subjects With Systemic Sclerosis Posted To Clinical Trials Website On 2024-03-25; Study Is Not Yet Recruiting

Inclusion Criteria: Age ≥18 and ≤70A clinical diagnosis of SSc, based on the 2013 American College of Rheumatology and European League Against Rheumatism classification criteria.Early active diseaseEv

BenzingaMar 25 22:25

Cabaletta Bio Inc (CABA) Earnings: Aligns With EPS Projections, Forecasts Extended Cash Runway

Yahoo FinanceMar 23 17:31

Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $50 Price Target

Cantor Fitzgerald analyst Joshua Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $50 price target.

BenzingaMar 23 01:54

Cabaletta Bio Price Target Raised to $35.00/Share From $34.00 by Wells Fargo

Cabaletta Bio Price Target Raised to $35.00/Share From $34.00 by Wells Fargo

Dow JonesMar 23 01:50

Cabaletta Bio Is Maintained at Buy by HC Wainwright & Co.

Cabaletta Bio Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMar 22 23:05

HC Wainwright & Co. Maintains Buy on Cabaletta Bio, Raises Price Target to $30

HC Wainwright & Co. analyst Douglas Tsao maintains Cabaletta Bio with a Buy and raises the price target from $25 to $30.

Analyst UpgradesMar 22 22:55

Strong Buy on Cabaletta Bio: Promising CAR T Candidate and Robust Financial Outlook

TipRanksMar 22 18:15

Wells Fargo Releases a Buy Rating on Cabaletta Bio (CABA)

TipRanksMar 22 17:18

Cabaletta Bio Earns 'Buy' Rating on Impressive Clinical Progress and Strategic Market Positioning

TipRanksMar 22 01:05

Cabaletta Bio (CABA) Gets a Buy From TD Cowen

TipRanksMar 21 23:35

Cabaletta Bio Files Automatic Mixed Securities Shelf

Seeking AlphaMar 21 23:01

Recap: Cabaletta Bio Q4 Earnings

Cabaletta Bio (NASDAQ:CABA) reported its Q4 earnings results on Thursday, March 21, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsCabaletta Bio missed estimated ea

BenzingaMar 21 21:10

Cabaletta Bio Q4 EPS $(0.46) Misses $(0.39) Estimate; Cabaletta Had Cash, Cash Equivalents And Short-term Investments Of $241.2M Expected To Fund Its Operating Plan Into The First Half Of 2026

Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.39) by 17.95 percent. This is a 188.46 percent decrease over earnings of $

BenzingaMar 21 19:22

Cabaletta Bio GAAP EPS of -$0.46

Seeking AlphaMar 21 19:08

Cabaletta Bio 4Q Research and Development Expenses $17.4M >CABA

Cabaletta Bio 4Q Research and Development Expenses $17.4M >CABA

Dow JonesMar 21 19:02